Hamrick Investment Counsel’s Novartis NVS Stock Holding History

Hamrick Investment Counsel’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.3K	Hold	100	–	–	0.01%	216
2025 Q4	$13.8K	Buy	+100	New	+$13.1K	0.01%	126

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hamrick Investment Counsel's NVS Position: Q1 2026 in Review

Hamrick Investment Counsel held its Novartis (NVS) position steady in Q1 2026 at 100 shares worth $15.3K. The position accounts for 0.01% of the portfolio, ranked #216.

Hamrick Investment Counsel first reported a position in NVS in Q4 2025 and has held it in 2 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Hamrick Investment Counsel held 100 shares of Novartis worth $15.3K as of Q1 2026.
Hamrick Investment Counsel left its Novartis share count unchanged in Q1 2026.
Novartis made up 0.01% of Hamrick Investment Counsel's portfolio in Q1 2026, its #216 holding.
Hamrick Investment Counsel first reported a position in Novartis in Q4 2025 and has held it in 2 quarters since.
1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Hamrick Investment Counsel's 13F filing for Q1 2026, filed 11 May 2026.